Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 246.66% | 140.41% | 31.60% | 13.84% | 0.22% |
| Total Depreciation and Amortization | -1.82% | 31.60% | 15.81% | 8.08% | 38.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -9.84% | 1.11% | -25.30% | 59.21% | 96.37% |
| Change in Net Operating Assets | -664.73% | 90.03% | -155.59% | -150.89% | -377.85% |
| Cash from Operations | -19.20% | 335.05% | 15.02% | -9.65% | -63.06% |
| Capital Expenditure | -14.67% | 89.17% | 75.95% | 68.95% | 84.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -977.83% | -292.12% | 2.31% | -336.54% | -61.92% |
| Cash from Investing | -1,117.24% | -316.10% | 5.95% | -429.69% | -51.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.31% | 1,148.44% | -98.64% | 3,955.33% | 1,266.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -112.06% | -- | -- | -- |
| Cash from Financing | -94.31% | -97.58% | -98.64% | 8,068.58% | 1,266.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -419.16% | 42.73% | 39.48% | 263.22% | -816.59% |